Virodhamine 

Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases^[1][2].

Virodhamine (50 nM; 72 h) increases adherence, membrane expansion and the size of nucleus^[1].
Virodhamine (10-40 μM; 72 h) increases the expression level of CD61 and TRPV1^[1].
Virodhamine (72 h) inhibits the cell proliferation of megakaryocyte cells and significantly increases the portion of high ploidy cells as compared to control^[1].
Virodhamine significantly increases the protein expression level of CB2 receptorn, ROS production and NAPDH oxidase NOX4 expression in megakaryocytic cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Virodhamine (1-10 mg/kg; i.p. once) repairs the nicotine (0.8 mg/kg) and immobilization stress induced anxiety in vivo^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

347.53

C₂₂H₃₇NO₂

287937-12-6

粘稠液体

Yellow to brown

Room temperature in continental US; may vary elsewhere.

• [1]. Sharma DS, et al. Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria. J Cell Physiol. 2021 Feb;236(2):1445-1453.  [Content Brief]

  [2]. Hayase T. Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. BMC Neurosci. 2013 Feb 9;14:20.  [Content Brief]